PL3316856T3 - Zmieszane formulacje - Google Patents

Zmieszane formulacje

Info

Publication number
PL3316856T3
PL3316856T3 PL16733592T PL16733592T PL3316856T3 PL 3316856 T3 PL3316856 T3 PL 3316856T3 PL 16733592 T PL16733592 T PL 16733592T PL 16733592 T PL16733592 T PL 16733592T PL 3316856 T3 PL3316856 T3 PL 3316856T3
Authority
PL
Poland
Prior art keywords
blended formulations
blended
formulations
Prior art date
Application number
PL16733592T
Other languages
English (en)
Inventor
William Henry
Richard Wolf GARRAWAY
Original Assignee
Sequessome Technology Holdings Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1511469.7A external-priority patent/GB201511469D0/en
Priority claimed from GBGB1511478.8A external-priority patent/GB201511478D0/en
Application filed by Sequessome Technology Holdings Limited filed Critical Sequessome Technology Holdings Limited
Publication of PL3316856T3 publication Critical patent/PL3316856T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/618—Salicylic acid; Derivatives thereof having the carboxyl group in position 1 esterified, e.g. salsalate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/04—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/14—Liposomes; Vesicles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Birds (AREA)
  • Biochemistry (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PL16733592T 2015-06-30 2016-06-30 Zmieszane formulacje PL3316856T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB1511469.7A GB201511469D0 (en) 2015-06-30 2015-06-30 Compositions
GBGB1511478.8A GB201511478D0 (en) 2015-06-30 2015-06-30 Blended formulations
PCT/EP2016/065415 WO2017001617A1 (en) 2015-06-30 2016-06-30 Blended formulations
EP16733592.6A EP3316856B1 (en) 2015-06-30 2016-06-30 Blended formulations

Publications (1)

Publication Number Publication Date
PL3316856T3 true PL3316856T3 (pl) 2021-10-25

Family

ID=56292753

Family Applications (2)

Application Number Title Priority Date Filing Date
PL16733595T PL3316857T3 (pl) 2015-06-30 2016-06-30 Kompozycje wielofazowe
PL16733592T PL3316856T3 (pl) 2015-06-30 2016-06-30 Zmieszane formulacje

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL16733595T PL3316857T3 (pl) 2015-06-30 2016-06-30 Kompozycje wielofazowe

Country Status (14)

Country Link
US (5) US10744090B2 (pl)
EP (3) EP3954361A1 (pl)
JP (2) JP6851998B2 (pl)
CA (2) CA3026466A1 (pl)
DK (2) DK3316857T3 (pl)
EA (2) EA038208B1 (pl)
ES (2) ES2879383T3 (pl)
HR (2) HRP20211669T1 (pl)
HU (2) HUE054749T2 (pl)
LT (2) LT3316856T (pl)
MX (4) MX382034B (pl)
PL (2) PL3316857T3 (pl)
PT (2) PT3316856T (pl)
WO (2) WO2017001617A1 (pl)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10744090B2 (en) 2015-06-30 2020-08-18 Sequessome Technology Holdings Limited Multiphasic compositions
WO2017136600A1 (en) 2016-02-04 2017-08-10 ALASTIN Skincare, Inc. Compositions and methods for invasive and non-invasive procedural skincare
EP3661538A4 (en) 2017-08-03 2021-07-14 Alastin Skincare, Inc. COMPOSITIONS AND PROCEDURES FOR IMPROVING SLEEPING SKIN AND BODY CONTOUR
EP4324460A3 (en) 2017-09-15 2024-04-24 Dyve Biosciences, Inc. Sodium bicarbonate for use in the treatment of gout and related disorders
WO2020028694A1 (en) 2018-08-02 2020-02-06 ALASTIN Skincare, Inc. Liposomal compositions and methods of use
JP2025099708A (ja) * 2023-12-22 2025-07-03 小林製薬株式会社 外用組成物

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4372296A (en) 1980-11-26 1983-02-08 Fahim Mostafa S Treatment of acne and skin disorders and compositions therefor
JPS60136511A (ja) 1983-12-26 1985-07-20 Eisai Co Ltd 高尿酸血症治療剤
EP0238554A4 (en) 1985-09-27 1987-10-27 Univ California SYSTEM FOR TRANSDERMAL DELIVERY OF MEDICAMENTS TO LIPOSOMES.
JPS6295134A (ja) 1985-10-21 1987-05-01 Nippon Saafuakutanto Kogyo Kk リポソ−ムの製造法
US5015483A (en) 1989-02-09 1991-05-14 Nabisco Brands, Inc. Liposome composition for the stabilization of oxidizable substances
US5498607A (en) 1990-07-30 1996-03-12 University Of Miami Treatment for hypercholesterolemia
US6165500A (en) 1990-08-24 2000-12-26 Idea Ag Preparation for the application of agents in mini-droplets
JP3765579B2 (ja) 1990-08-24 2006-04-12 イーデーエーアー アーゲー 作用物質投与用超微小滴状調剤
US5498420A (en) 1991-04-12 1996-03-12 Merz & Co. Gmbh & Co. Stable small particle liposome preparations, their production and use in topical cosmetic, and pharmaceutical compositions
JPH08509202A (ja) 1992-07-08 1996-10-01 ディアノルム―ゲレーテ・ゲー・マイエルホファー・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング リポソーム、それを調製する方法及び薬調製におけるその用途
FR2714382B1 (fr) 1993-12-27 1996-02-02 Roussel Uclaf Phospholipides vecteur de molécule active, leur préparation et leur utilisation dans des compositions cosmétiques ou dermatologiques.
FR2714596B1 (fr) 1993-12-30 1996-02-09 Oreal Composition cosmétique pour le traitement simultané des couches superficielles et profondes de la peau, son utilisation.
EP0789584B1 (de) 1994-11-04 2001-09-19 Polymun Scientific Immunbiologische Forschung GmbH Applikation von sod in liposomen
DE4447287C1 (de) 1994-12-30 1996-11-07 Cevc Gregor Präparat zum Wirkstofftransport durch Barrieren
US5902604A (en) 1995-06-06 1999-05-11 Board Of Regents, The University Of Texas System Submicron liposome suspensions obtained from preliposome lyophilizates
FR2767691B1 (fr) 1997-08-27 2000-02-18 Oreal Utilisation d'une dispersion a base de vehicules lipidiques comme composition anti-inflammatoire
IL122084A (en) * 1997-10-31 1999-09-22 Lurident Ltd Formulation for personal care with mucoadhesive properties
SK284338B6 (sk) 1997-11-19 2005-02-04 Schering Aktiengesellschaft Kompozícia s kyselinou azelaínovou
US6165997A (en) 1997-11-20 2000-12-26 Statens Serum Institut Phospholipids having antimicrobial activity with or without the presence of antimicrobials
AU1201099A (en) * 1998-01-16 1999-08-02 Color Access, Inc. Stabilized whitening compositions and method of preparing same
CN1322129A (zh) 1998-09-01 2001-11-14 伊迪亚股份公司 带电穿透剂通过屏障的电控转运
NZ332905A (en) 1998-11-19 2000-12-22 Immuno Lab Ltd Transdermal pharmaceutical composition comprising liposomal bee venom
CZ20012038A3 (cs) 1998-12-23 2001-09-12 Idea Ag Zdokonalený přípravek pro topické, neinvazivní použití in vivo
EP1031346B1 (en) 1999-01-27 2002-05-02 Idea Ag Noninvasive vaccination through the skin
GB9902527D0 (en) 1999-02-04 1999-03-24 Phares Pharm Res Nv Compositions
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
WO2001001962A1 (en) 1999-07-05 2001-01-11 Idea Ag. A method for the improvement of transport across adaptable semi-permeable barriers
US6248728B1 (en) 2000-03-10 2001-06-19 Kansas State University Research Foundation Phosphatidylcholine compositions and methods for lowering intestinal absorption and plasma levels of cholesterol
US6191121B1 (en) 2000-04-06 2001-02-20 Nicholas V. Perricone Treatment of skin damage using polyenylphosphatidylcholine
DK1272160T3 (da) 2000-04-12 2007-05-21 Liplasome Pharma As Lipidbaseret lægemiddelleveringssystem til topisk applikation
TWI281407B (en) 2000-09-18 2007-05-21 Vasogen Ireland Ltd Apoptosis-mimicking synthetic entities and use thereof in medical treatment
WO2002062316A1 (de) 2001-02-08 2002-08-15 Vectron Therapeutics Ag Invasomen zur therapie von erkrankungen, ihre herstellung und verwendung
WO2002096435A2 (en) 2001-05-31 2002-12-05 Pharmacia Corporation Skin-permeable composition comprising a selective cyclooxygenase-2 inhibitor a monohydric alcohol
JP2004535434A (ja) 2001-06-25 2004-11-25 デピユイ 関節炎にかかった関節の処置のためのグリコサミノグリカン類のリポソームカプセル化
CA2368656A1 (en) 2002-01-21 2003-07-21 Vasogen Ireland Limited Receptor-ligand pairing for anti-inflammatory response
AU2003233396B2 (en) 2002-03-13 2007-05-24 Thomas Skold Water-based delivery systems
BRPI0309457B1 (pt) * 2002-04-22 2017-02-21 Procter & Gamble composições para cuidados pessoais que contém um material contendo zinco em uma composição aquosa de tensoativo
US20040009180A1 (en) 2002-07-11 2004-01-15 Allergan, Inc. Transdermal botulinum toxin compositions
CN1470234A (zh) * 2002-07-23 2004-01-28 吴翠栓 皮肤用辣椒碱脂质体制剂
NZ538571A (en) 2002-10-11 2007-05-31 Idea Ag Aggregate with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin
US7473432B2 (en) 2002-10-11 2009-01-06 Idea Ag NSAID formulations, based on highly adaptable aggregates, for improved transport through barriers and topical drug delivery
JP2004131432A (ja) 2002-10-11 2004-04-30 Kumamoto Technology & Industry Foundation 悪性腫瘍抑制剤
AU2004235781A1 (en) 2003-05-02 2004-11-18 Aronex Pharmaceuticals, Inc. Lipid platinum complexes and methods of use thereof
EP1514539A3 (en) * 2003-05-14 2005-05-04 Signal Investment & Management Co. Micro-encapsulated topical analgesic for pain relief and sleeve comprising it
WO2005007169A2 (en) 2003-07-21 2005-01-27 Vasogen Ireland Limited Liposomes containing phosphate glycerol groups for treating acute inflammatory condition
JP2005179313A (ja) 2003-12-24 2005-07-07 Shu Uemura:Kk 皮膚化粧料用基剤の製造方法および皮膚化粧料
US7476432B2 (en) 2004-05-28 2009-01-13 Tecton Products Phosphorescent pultrusion
CA2584475A1 (en) 2004-11-12 2006-05-18 Idea Ag Extended surface aggregates in the treatment of skin conditions
WO2006086992A2 (en) 2005-02-18 2006-08-24 Liplasome Pharma A/S Drug delivery systems containing phqspholipase a2 degradable lipid prodrug derivatives and the therapeutic uses thereof as. e.g. wound healing agents and peroxisome proliferator activated receptor ligands
US20070042008A1 (en) 2005-08-18 2007-02-22 Bodybio, Inc. Compositions containing phosphatidylcholine and essential fatty acids
BRPI0615411A2 (pt) 2005-08-29 2012-12-04 Sepsicure L L C uso de um ácido da bìlis ou de um sal de ácido da bìlis e um fosfolipìdeo
PE20070335A1 (es) 2005-08-30 2007-04-21 Novartis Ag Benzimidazoles sustituidos y metodos para su preparacion
EP1968567B1 (en) 2005-12-20 2014-06-18 Cenestra, Llc Omega 3 fatty acid formulations
JP5009547B2 (ja) 2006-03-31 2012-08-22 株式会社コーセー 顔料とリポソームを含む化粧料
US7544375B1 (en) 2006-06-12 2009-06-09 Swiss Skin Repair, Inc. Composition
US20080131497A1 (en) * 2006-09-28 2008-06-05 Perkins Walter R Formulations of DNase and Methods of Use Thereof
CA2664944C (en) 2006-09-28 2016-06-14 Hadasit Medical Research Services & Development Limited Use of glycerophospholipids for joint lubrication
JP4732307B2 (ja) 2006-11-20 2011-07-27 株式会社アンズコーポレーション ナノエマルション及びそれを配合した化粧料
US20100130611A1 (en) 2006-12-20 2010-05-27 Cenestra Llc Omega 3 fatty acid formulations
EP1938801A1 (en) 2006-12-22 2008-07-02 Biofrontera Bioscience GmbH Nanoemulsion
US9511016B2 (en) 2007-06-12 2016-12-06 Epicentrx, Inc. Topical composition for treating pain
ITVR20080006A1 (it) 2008-01-23 2009-07-24 David Ceretta Apparato per la realizzazione di elementi d'impasto
ES2335636B1 (es) * 2008-02-29 2011-05-11 Lipotec, S.A. Composicion cosmetica o dermofarmaceutica de micelas mixtas.
JP2009256331A (ja) 2008-03-25 2009-11-05 Nagase Chemtex Corp 高尿酸血症、又は痛風の予防、改善、又は治療剤
US20100105139A1 (en) 2008-10-27 2010-04-29 Remco Alexander Spanjaard Ligand Targeted Nanocapsules for the delivery of RNAi and other Agents
CA2751412A1 (en) 2009-02-05 2010-08-12 Targeted Delivery Technologies Limited Methods of reducing the proliferation and viability of microbial agents
JP2012528846A (ja) 2009-06-03 2012-11-15 マヨ、ジョン、チャールズ 深部組織の痛みを治療するための製剤
GB2486371A (en) 2009-08-21 2012-06-13 Targeted Delivery Technologies Ltd Vesicular formulations
EP2382994A1 (en) 2010-04-26 2011-11-02 Maurizio Victor Cattaneo Ligand targeted nanocapsules for the delivery of RNAi and other agents
WO2011162802A1 (en) 2010-06-21 2011-12-29 Virun, Inc. Compositions containing non-polar compounds
US20120045405A1 (en) 2010-08-18 2012-02-23 Gilman Miles E Under eye cream
WO2012148891A1 (en) 2011-04-29 2012-11-01 Evonik Degussa Corporation Peptide-lipid conjugates and uses thereof
GB201205642D0 (en) 2012-03-29 2012-05-16 Sequessome Technology Holdings Ltd Vesicular formulations
GB201206486D0 (en) 2012-04-12 2012-05-30 Sequessome Technology Holdings Ltd Vesicular formulations and uses thereof
GB201208384D0 (en) 2012-05-14 2012-06-27 Sequessome Technology Holdings Ltd Vesicular formulations, uses and methods
GB201208409D0 (en) 2012-05-14 2012-06-27 Sequessome Technology Holdings Ltd Vesicular formulations, kits and uses
SG11201600424VA (en) 2013-07-31 2016-02-26 Sequessome Technology Holdings Ltd Vesicles
US10744090B2 (en) 2015-06-30 2020-08-18 Sequessome Technology Holdings Limited Multiphasic compositions
JP2022535143A (ja) * 2019-06-04 2022-08-04 アクアヴィット ファーマシューティカルズ,インコーポレイテッド マイクロチャネル技術を使用してヒアルロン酸で皮膚をマイクロフィルするための方法および組成物

Also Published As

Publication number Publication date
ES2879383T3 (es) 2021-11-22
PT3316856T (pt) 2021-07-06
JP2018522876A (ja) 2018-08-16
EA038208B1 (ru) 2021-07-23
HRP20210903T1 (hr) 2021-09-17
CA3026466A1 (en) 2017-01-05
MX2018000024A (es) 2018-06-27
WO2017001625A1 (en) 2017-01-05
DK3316857T3 (da) 2021-10-18
HK1254980A1 (zh) 2019-08-02
US10744090B2 (en) 2020-08-18
EA201890120A1 (ru) 2018-07-31
WO2017001617A1 (en) 2017-01-05
PT3316857T (pt) 2021-11-03
HRP20211669T1 (hr) 2022-02-18
US20190167588A1 (en) 2019-06-06
EP3316856A1 (en) 2018-05-09
HUE056161T2 (hu) 2022-01-28
CA3026484A1 (en) 2017-01-05
JP6851998B2 (ja) 2021-03-31
LT3316857T (lt) 2021-11-25
US20210007989A1 (en) 2021-01-14
EP3316857A1 (en) 2018-05-09
EA201890119A1 (ru) 2018-07-31
US20210023007A1 (en) 2021-01-28
LT3316856T (lt) 2021-07-12
MX2018000021A (es) 2018-03-15
PL3316857T3 (pl) 2022-01-31
US20240099976A1 (en) 2024-03-28
EA038613B1 (ru) 2021-09-23
US20220370353A9 (en) 2022-11-24
EP3316856B1 (en) 2021-04-07
EP3954361A1 (en) 2022-02-16
MX2021003510A (es) 2021-05-27
DK3316856T3 (da) 2021-06-28
EP3316857B1 (en) 2021-08-04
US11547665B2 (en) 2023-01-10
HUE054749T2 (hu) 2021-09-28
HK1254979A1 (zh) 2019-08-02
JP2021091730A (ja) 2021-06-17
ES2895910T3 (es) 2022-02-23
MX382034B (es) 2025-03-13
MX2021004766A (es) 2022-11-07
MX381075B (es) 2025-03-12
US20180311148A1 (en) 2018-11-01

Similar Documents

Publication Publication Date Title
IL273541A (en) formulations
IL273282A (en) Niraprib formulations
IL269630A (en) Niraprib formulations
IL269621A (en) Niraparib formulations
SG10202106970XA (en) Stable anti-ifnar1 formulation
IL265609A (en) New formulations
GB201607918D0 (en) Novel formulations
GB201419091D0 (en) Formulations
GB201419261D0 (en) Formulations
GB201514758D0 (en) Formulation
PT3316856T (pt) Formulações misturadas
ES2873376T5 (en) Maropitant formulation
PL3443034T3 (pl) Kompozycja
GB201521771D0 (en) Formulation
GB201511255D0 (en) Formulation
GB201509891D0 (en) Formulation
GB201504482D0 (en) Novel formulations
GB201511478D0 (en) Blended formulations
GB201621277D0 (en) Formulations
GB201714461D0 (en) Formulations
GB201618110D0 (en) Formulations
GB201616366D0 (en) Formulations
GB201615754D0 (en) Formulations
GB201507784D0 (en) Formulations
GB201505532D0 (en) Formulations